TOBI Podhaler FDA Approval History
FDA Approved: Yes (First approved March 22, 2013)
Brand name: TOBI Podhaler
Generic name: tobramycin
Dosage form: Inhalation Powder
Company: Novartis Pharmaceuticals Corporation
Treatment for: Cystic Fibrosis
TOBI Podhaler (tobramycin inhalation powder) is an antibacterial aminoglycoside indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.
Development Timeline for TOBI Podhaler
|Mar 24, 2013||FDA Approves TOBI Podhaler to Treat a Type of Bacterial Lung Infection in Cystic Fibrosis Patients|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.